Market Overview

ARDM INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Aradigm Corporation Investors

Share:

Law Offices of Howard G. Smith announces that a class action lawsuit has
been filed on behalf of investors that purchased Aradigm
Corporation ("Aradigm" or the "Company") (NASDAQ: ARDM)
securities between July 27, 2017 and January 8, 2018, inclusive
(the "Class Period"). Aradigm investors have until March 12, 2018 to
file a lead plaintiff motion.

Investors suffering losses on their Aradigm investments are encouraged
to contact the Law Offices of Howard G. Smith to discuss their legal
rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

On January 9, 2018, the U.S. Food and Drug Administration ("FDA")
released its briefing document for the January 11, 2018 meeting of the
Antimicrobial Drugs Advisory Committee to discuss the New Drug
Application for Linhaliq™ for the proposed indication of treatment of
non-cystic fibrosis bronchiectasis ("NCFB"). The FDA stated that "there
were too many uncertainties with regard to duration of treatment,
frequency of administration and endpoints to allow for reliance on a
single Phase 3 trial" of the drug, and that the FDA recommended Aradigm
conduct "two independent trials" to provide evidence supporting the
drug's "overall demonstration of efficacy and safety." On this news,
Aradigm's share price fell $2.28, or 38.12%, to close at $3.70 per share
on January 9, 2018.

The complaint filed in this class action alleges that throughout the
Class Period, Defendants made materially false and misleading statements
regarding the Company's business, operational and compliance policies.
Specifically, Defendants made false and/or misleading statements and/or
failed to disclose that: (i) the methodology underlying Aradigm's
Linhaliq Phase III clinical trials was not well tailored to yield
consistent efficacy findings or to provide data sufficient to account
for discordant efficacy findings; (ii) the endpoint of the Phase III
trials - namely, delaying the time to first exacerbation on study
therapy compared to placebo over approximately one year of observation -
was unlikely to demonstrate a clinically meaningful benefit with respect
to a patient population that would likely be taking the drug for a
longer duration; (iii) accordingly, these studies were unlikely to
support FDA approval of the Linhaliq NDA; and (iv) as a result,
Aradigm's public statements were materially false and misleading at all
relevant times.

If you purchased shares of Aradigm, have information or would like to
learn more about these claims, or have any questions concerning this
announcement or your rights or interests with respect to these matters,
please contact Howard G. Smith, Esquire, of Law Offices of Howard G.
Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by
telephone at 215-638-4847, toll-free at 888-638-4847, or by email to howardsmith@howardsmithlaw.com,
or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com